文献速递系统性红斑狼疮

蛋白甘露糖基化作为狼疮肾炎诊断与预后生物标志物

Protein Mannosylation as a Diagnostic and Prognostic Biomarker of Lupus Nephritis: An Unusual Glycan Neoepitope in Systemic Lupus Erythematosus.
PubMed 文献 · Arthritis Rheumatol · 2021-09-28

本研究对系统性红斑狼疮合并活检证实狼疮肾炎(LN)患者的肾脏标本进行组织糖组学分析,发现LN具有独特的富甘露糖聚糖特征,该特征不见于其他肾脏疾病,且诊断时肾活检甘露糖基化水平可预测慢性肾脏病(CKD)发生,特异度达93%。

要点

  • LN肾脏组织呈现独特的富甘露糖聚糖特征,在其他肾脏疾病中未观察到。
  • 该异常源于复杂N-糖基化通路缺陷与O-甘露糖基化通路活跃。
  • 诊断时肾活检甘露糖基化水平预测CKD发生,特异度93%。

核心结论

  • 细胞甘露糖基化是狼疮肾炎的标志,可预测慢性肾脏病发生,有望作为糖生物标志物纳入LN诊断与预后评估体系。

研究设计与样本

  • 对系统性红斑狼疮及活检证实狼疮肾炎患者的肾脏标本进行组织糖组学表征,结合先进组织质谱、原位糖表征与离体糖表型分析,结构映射LN组织样本的N-聚糖谱。

主要发现

  • LN呈现独特聚糖特征,即通常见于低等微生物的异常富甘露糖聚糖丰度增加且空间分布特异,该特征为LN所特有,其他肾脏疾病中未观察到。
  • LN中甘露糖基化聚糖暴露于肾细胞表面,促进免疫细胞表达的特定聚糖识别受体对其识别。
  • 该异常糖特征源于复杂N-糖基化通路缺陷与O-甘露糖基化通路活跃。
  • 诊断时LN患者肾活检样本所测甘露糖基化水平可预测慢性肾脏病发生,特异度93%。

关键数值与推荐

  • LN诊断时肾活检甘露糖基化水平预测慢性肾脏病发生的特异度为93%。

临床怎么用

  • 可考虑将肾组织甘露糖基化检测纳入LN诊断与预后评估流程,用于识别CKD高风险患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Changes in protein glycosylation are a hallmark of immune-mediated diseases. Glycans are master regulators of the inflammatory response and are important molecules in self-nonself discrimination. This study was undertaken to investigate whether lupus nephritis (LN) exhibits altered cellular glycosylation to identify a unique glycosignature that characterizes LN pathogenesis. METHODS: A comprehensive tissue glycomics characterization was performed in kidney specimens from patients with systemic lupus erythematosus and biopsy-proven LN. A combination of advanced tissue mass spectrometry, in situ glyco-characterization, and ex vivo glycophenotyping was performed to structurally map the repertoire of N-glycans in LN tissue samples. RESULTS: LN exhibited a unique glycan signature characterized by increased abundance and spatial distribution of unusual mannose-enriched glycans that are typically found in lower microorganisms. This glycosignature was specific for LN, as it was not observed in other kidney diseases. Exposure of mannosylated glycans in LN was shown to occur at the cell surface of kidney cells, promoting increased recognition by specific glycan-recognizing receptors expressed by immune cells. This abnormal glycosignature of LN was shown to be due to a deficient complex N-glycosylation pathway and a proficient O-mannosylation pathway. Moreover, mannosylation levels detected in kidney biopsy samples from patients with LN at the time of diagnosis were demonstrated to predict the development of chronic kidney disease (CKD) with 93% specificity. CONCLUSION: Cellular mannosylation is a marker of LN, predicting the development of CKD, and thus representing a potential glycobiomarker to be included in the diagnostic and prognostic algorithm of LN.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Alves I, Santos-Pereira B, Dalebout H, et al. Protein Mannosylation as a Diagnostic and Prognostic Biomarker of Lupus Nephritis: An Unusual Glycan Neoepitope in Systemic Lupus Erythematosus. Arthritis Rheumatol. 2021. PMID: 33881228. doi:10.1002/art.41768

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。